Diese Präsentation wurde erfolgreich gemeldet.
Wir verwenden Ihre LinkedIn Profilangaben und Informationen zu Ihren Aktivitäten, um Anzeigen zu personalisieren und Ihnen relevantere Inhalte anzuzeigen. Sie können Ihre Anzeigeneinstellungen jederzeit ändern.

Fogsi Guidelines

2.385 Aufrufe

Veröffentlicht am

Veröffentlicht in: Gesundheit & Medizin
  • Als Erste(r) kommentieren

Fogsi Guidelines

  1. 1. FOGSI RECOMMENDATIONS FOR CERVICAL CANCER VACCINATION 11 th OCTOBER 2008 DR. JYOTI BHASKAR Director Lifecare IVF Consultant Pushpanjali Crosslay Hospital
  2. 2. VACCINATION TARGET GROUP • • • • • APPROVED Bivalent 10-45 YRS Quadrivalent 9-45 yrs Most convenient and optimal age (12-16 years old) – before first sexual exposure Offered to all upto 45 years, regardless of sexual activity but less effective if sexually active. Informed discussion between the woman and her health care provider Not recommended in males
  3. 3. COUNSELLING • • • • • Full explanation of the role, action and usefulness of the vaccine the role of HPV in cervical carcinogenesis (in particular HPV-16 and HPV-18); It is NOT therapeutic trial results and expectations; immunological responses; safety and efficacy; as well as answer queries on issues
  4. 4. DOSAGE SCHEDULE BIVALENT • 0, 1, 6 months QUADRIVALENT • 0, 2, 6 months Minimum Intervals between doses • 4 weeks between 1st & 2nd dose • 12 weeks between 2nd and 3rd dose ADMINISTRATION: 1. Intramuscularly in deltoid Muscle 2. In lying down position and observe for 15 mts
  5. 5. HPV TESTING • Before Vaccination not recommended • Vaccinated women should be screened as per the standard guideline • Screen positive women may be vaccinated after counseling
  6. 6. Sexually Active Women • Sexually active women and women with previous abnormal cervical cytology can receive the HPV vaccine • Benefits may be limited to the protection against infection of HPV genotypes with which they have not been infected
  7. 7. SPECIAL SITUATION PREVIOUS CIN • Should be Vaccinated • Counselled - the benefits may be limited to the protection against infection of HPV genotypes (and related CIN) with which they have not been infected. • Cervical screening and corresponding management must continue.
  8. 8. IMMUNOCOMPROMISED PATIENTS • Not a contraindication to vaccination. • Immune response to the HPV vaccine may be less competent.
  9. 9. PREGNANCY AND LACTATION • The use of the vaccine in pregnancy is not recommended, although no teratogenic effect caused by the vaccine has been reported. • There is no evidence to show that the HPV vaccine adversely affects fertility, pregnancy or infant outcome. • Women who are planning to conceive are advised to defer vaccination until after delivery.
  10. 10. PREGNANCY AND LACTATION • Women who become pregnant before completion of vaccination are advised to postpone the remaining dose until after the pregnancy. • Termination of pregnancy is not indicated for women who become inadvertently pregnant during the course of vaccination. • Lactating women can receive the HPV vaccine and still continue breastfeeding because it is a vaccine without live viral DNA.
  11. 11. Clinical Efficacy Use of CIN grade 2 or 3 (CIN2–3) and AIS as clinical end-points in vaccine efficacy trials instead of invasive cervical cancer
  12. 12. Contraindications and Precautions • History of hypersensitivity to any vaccine component. • Women with moderate or severe acute illnesses should be deferred until after the illness improves. • If administered concomitantly with any other vaccine, it should be at a separate site, with a separate syringe
  13. 13. "There are challenges for countries in terms of cost and so on, but this vaccine is unique and offers tremendous possibilities." Dr Teresa Aguado, WHO’s coordinator for the Initiative for Vaccine Research, Product Research and Development team.